Genfit SA has established a research collaboration with Everzom SAS to expand its acute-on-chronic liver failure (ACLF) research via exosome-based regenerative technology. The partners plan to conduct exploratory studies to assess efficacy of Everzom’s investigational drug candidate Eviv in ACLF.